PTI Proteostasis Therapeutics Inc

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today reported financial results for the third quarter ended September 30, 2016.

Revenue was $1.7 million for the three months ended September 30, 2016, compared to $1.2 million for the three months ended September 30, 2015. The increase was the result of an increase in revenue recognized from the Company’s collaboration with Astellas.

Research and development expenses were $9.2 million for the three months ended September 30, 2016, compared to $6.3 million for the three months ended September 30, 2015. The increase was primarily due to an increase of $2.6 million related to activities supporting the Company’s Phase 1 clinical trials of PTI-428 which commenced during the first quarter of 2016.

General and administrative expenses were $3.3 million for the three months ended September 30, 2016, compared to $1.5 million for the three months ended September 30, 2015. The increase was primarily due to a $0.8 million increase in personnel-related costs, a $0.6 million increase in professional fees and a $0.3 million increase in occupancy and other facility-related costs.

Net loss was $10.8 million for the three months ended September 30, 2016, compared to $7.1 million for the three months ended September 30, 2015. The increase in net loss was primarily attributable to the increase in operating expenses noted above.

Cash, cash equivalents and short-term investments were $100.2 million as of September 30, 2016, including the proceeds from the Company’s follow-on public offering in the third quarter of 2016. In September 2016, the Company closed its follow-on public offering of 5,750,000 shares of its common stock at a public offering price of $13.00 per share. The net proceeds from the offering were $69.5 million, after deducting the underwriting discount and expenses associated with the offering payable by the Company.

Based on the Company’s current operating plan, the Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditures requirements through the second quarter of 2018.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery of groundbreaking therapies to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis Therapeutics team focuses on identifying therapies that modulate the proteostasis imbalance in cells and restore protein function. Proteostasis Therapeutics is currently enrolling eligible adults with CF to participate in its Phase 1 clinical trials of PTI-428. In addition to its multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed collaborations with Biogen to research and identify therapeutic candidates for neurodegenerative disease and with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. For more information, visit www.proteostasis.com.

Safe HarborTo the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward-looking statements made in this release include, without limitation, statements regarding the sufficiency of our cash balances to fund our operating and capital expenses through an expected date.  Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.  Such risks and uncertainties include, without limitation, uncertainties inherent in the execution and completion of clinical trials, in the timing of availability of trial data, in the actions of regulatory agencies, and those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, and our other SEC filings.  We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PROTEOSTASIS THERAPEUTICS, INC.
BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
		September 30,				December 31,
		2016				2015
Assets
Current assets:
Cash and cash equivalents		$	43,828			$	13,844
Short-term investments			56,412				—
Accounts receivable			445				918
Other current assets			2,388				180
Total current assets			103,073				14,942
Property and equipment, net			342				566
Deferred offering costs			—				2,744
Other assets			81				144
Restricted cash			294				294
Total assets		$	103,790			$	18,690
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable		$	2,809			$	3,330
Accrued expenses			4,182				2,248
Deferred revenue			4,683				4,076
Deferred rent			196				182
Total current liabilities			11,870				9,836
Deferred revenue, net of current portion			1,666				4,265
Deferred rent, net of current portion			139				287
Preferred stock warrant liability			—				110
Derivative liability			142				2
Total liabilities			13,817				14,500
Commitments and contingencies (Note 9)
Convertible preferred stock, (Series A and B), $0.001 par value; 0 and 110,057,398  shares authorized as of September 30, 2016 and December 31, 2015, respectively;  0 and 104,854,769 shares issued and outstanding as of September 30, 2016 and  December 31, 2015, respectively; aggregate liquidation preference of $0 and  $149,392, respectively, as of September 30, 2016 and December 31, 2015			—				112,292
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; 5,000,000 and 0 shares authorized  as of September 30, 2016 and December 31, 2015, respectively; no shares issued  and outstanding as of September 30, 2016 and December 31, 2015			—				—
Common stock, $0.001 par value; 125,000,000 and 170,000,000 shares authorized  as of September 30, 2016 and December 31, 2015, respectively; 24,945,125 and  571,137 shares issued and outstanding as of September 30, 2016 and December  31, 2015, respectively			26				1
Additional paid-in capital			237,989				12,115
Accumulated other comprehensive loss			(9	)			—
Accumulated deficit			(148,033	)			(120,218	)
Total stockholders’ equity (deficit)			89,973				(108,102	)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)		$	103,790			$	18,690

PROTEOSTASIS THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2016				2015				2016				2015
Revenue		$	1,715			$	1,201			$	4,324			$	3,078
Operating expenses:
Research and development			9,218				6,258				23,498				16,737
General and administrative			3,266				1,523				8,682				4,553
Total operating expenses			12,484				7,781				32,180				21,290
Loss from operations			(10,769	)			(6,580	)			(27,856	)			(18,212	)
Interest income			36				—				56				—
Interest expense			—				(189	)			—				(599	)
Other expense, net			(38	)			(281	)			(15	)			(598	)
Net loss			(10,771	)			(7,050	)			(27,815	)			(19,409	)
Modification of Series A preferred stock			—				174				—				10,739
Accruing dividends on preferred stock			—				(2,459	)			(1,378	)			(6,698	)
Net loss attributable to common stockholders		$	(10,771	)		$	(9,335	)		$	(29,193	)		$	(15,368	)
Net loss per share attributable to common stockholders—basic and diluted		$	(0.54	)		$	(16.77	)		$	(1.75	)		$	(28.05	)
Weighted average common shares outstanding—basic and diluted			20,073,685				556,567				16,672,368				547,816

Media Contact: 
Katie Engleman, Pure Communications, Inc.

(910) 509-3977 
katie@purecommunicationsinc.com

Investor Contact:
Luke Heagle, Pure Communications, Inc.
(910) 726-1372
luke@purecommunicationsinc.com